Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs…
News
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
– Neuroendocrine Prostate Cancer is Growing Unmet Medical Need – NEW YORK, Aug. 24, 2022 (GLOBE…
Catalyst Pharmaceuticals To Participate in Citi’s 17th Annual BioPharma Conference
CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a…
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader…
Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies
• The National Screening Laboratory of Sanquin Blood Supply Foundation joins MosaiQ Innovator’s Circle JERSEY,…
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and…
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth…
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical…
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with…
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study…
Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
– Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will…
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
New Science Technology Accelerates Patient Recruitment and Enrollment
Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient…
Repligen To Host Investor Day 2022
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a leading innovator of…
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL…
Agios to Participate in September Investor Conferences
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader…
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the…
BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], today announced that it…
New 835 Area Code is Coming to the 484/610 Region in Southeast Pennsylvania
BASKING RIDGE, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) — All customers with a 484 or…